Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POMALIDOMIDE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Multiple myeloma, relapsed or refractory (in combination with dexamethasone),Multiple myeloma, maintenance therapy post-autologous stem cell transplant,AIDS-related Kaposi sarcoma (off-label),Primary effusion lymphoma (off-label)
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal half-life approximately 7.5 hours in patients with normal renal function; prolonged to 9-12 hours in moderate renal impairment.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily metabolized by CYP1A2 and CYP3A4; undergoes glucuronidation via UGT1A8.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal (73% as unchanged drug and metabolites), fecal (15%), biliary (minimal).
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
12-44% bound to albumin and alpha-1-acid glycoprotein; mean ~30%.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
62-138 L (approx 0.8-1.7 L/kg); indicates extensive tissue distribution.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 73% (range 56-85%); high fat meal reduces AUC by 13% but no significant effect.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Cr Cl 30-59 m L/min: 3 mg once daily. Cr Cl <30 m L/min: 2 mg once daily. Not recommended if Cr Cl <15 m L/min or requiring dialysis.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: 4 mg once daily. Child-Pugh B: 2 mg once daily. Child-Pugh C: 1 mg once daily.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Safety and efficacy not established; no recommended dosing.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
No specific dose adjustment; monitor for increased toxicity (e.g., myelosuppression, neurotoxicity) due to age-related organ function decline.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
WARNING: EMBRYO-FETAL TOXICITY, VENOUS AND ARTERIAL THROMBOEMBOLISM, HEPATOTOXICITY, and INCREASED MORTALITY IN MULTIPLE MYELOMA. Pomalidomide is contraindicated in pregnant women due to teratogenicity. Thromboembolic events (DVT, PE, MI, stroke) are increased. Hepatotoxicity may be severe. In multiple myeloma clinical trials, pomalidomide/dexamethasone was associated with increased mortality in patients with high-risk cytogenetics (del 17p, t(4;14), t(14;16)).
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Embryo-fetal toxicity (must use contraception); venous/arterial thromboembolism (consider prophylaxis); hepatotoxicity (monitor LFTs); increased mortality in high-risk multiple myeloma; hematologic toxicity (neutropenia, thrombocytopenia); cardiac toxicity (arrhythmias, heart failure); severe cutaneous reactions; tumor lysis syndrome; renal impairment; fetal risk during pregnancy; avoid use in patients with prior hypersensitivity to thalidomide analogs.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Pregnancy (absolute); women of childbearing potential not using effective contraception; men not using condoms during sexual activity with pregnant or non-pregnant women; hypersensitivity to pomalidomide or thalidomide analogs; prior severe dermatologic reactions to pomalidomide.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid grapefruit juice and grapefruit products. Take with water, not with food to reduce nausea.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
First trimester: High risk of severe birth defects (e.g., limb anomalies, neural tube defects) due to potent teratogenicity; absolutely contraindicated. Second/third trimester: Risk of fetal harm persists; no safe level established; discontinue if possible.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
No data on M/P ratio; excreted in animal milk; potential for serious adverse reactions in infant; breastfeeding contraindicated during therapy and for at least 7 days after last dose.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No specific dose adjustments in pregnancy due to contraindication; pharmacokinetic changes (e.g., increased clearance) theoretically require higher doses if used, but teratogenicity prohibits use; avoid exposure entirely.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Thromboprophylaxis with aspirin or low molecular weight heparin is mandatory due to high VTE risk. Monitor CBC and thyroid function monthly. Contraindicated in pregnancy due to teratogenicity. Pomalidomide requires REMS program enrollment. Dose reduction needed for renal impairment (Cr Cl <45 m L/min).
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Do not become pregnant while taking this drug; use two reliable forms of contraception.,Report any signs of bleeding or bruising, as pomalidomide can cause low platelet counts.,Avoid grapefruit and grapefruit juice as they may increase drug levels.,Take capsules whole, not crushed or chewed, with water.,Do not donate blood during treatment and for 4 weeks after stopping.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Dextropropoxyphene, an opioid analgesic, and pomalidomide, an immunomodulatory agent, both pose risks of QT interval prolongation. Co-administration may result in additive QT prolongation, increasing the risk of torsade de pointes, a potentially fatal ventricular arrhythmia. Additionally, dextropropoxyphene may exacerbate the sedative and respiratory depressant effects of pomalidomide, leading to excessive central nervous system depression."
"Concomitant use of pomalidomide and perampanel may result in additive central nervous system (CNS) depression due to their independent sedative properties. Pomalidomide, an immunomodulatory drug, is associated with somnolence and fatigue, while perampanel, an AMPA receptor antagonist, commonly causes dizziness, somnolence, and ataxia. This combination can lead to excessive sedation, impaired cognitive function, and increased risk of falls or accidents, particularly in elderly patients or those with impaired hepatic function."
"The concurrent use of desflurane, a halogenated inhalational anesthetic, with pomalidomide, an immunomodulatory agent, may potentiate the risk of severe hypotension and bradycardia due to additive cardiovascular depression. Desflurane directly depresses myocardial contractility and systemic vascular resistance, while pomalidomide can induce vasodilation and negative chronotropic effects. Clinically, patients may experience profound drops in blood pressure and heart rate, leading to reduced cardiac output and potential end-organ hypoperfusion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POMALIDOMIDE vs ACTIQ, answered by our medical review team.
POMALIDOMIDE is a Immunomodulatory Agent that works by Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POMALIDOMIDE and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POMALIDOMIDE is: 4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POMALIDOMIDE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POMALIDOMIDE is classified as Category C. First trimester: High risk of severe birth defects (e.g., limb anomalies, neural tube defects) due to potent teratogenicity; absolutely contraindicated. Second/third trimester: Ris. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.